USD 1.16
(-4.92%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 1.57 Million USD | -24.53% |
2022 | 2.08 Million USD | 69333.33% |
2021 | 3000.00 USD | -99.04% |
2020 | 311 Thousand USD | -54.42% |
2019 | 682.31 Thousand USD | 5009.41% |
2018 | 13.35 Thousand USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | -100.0% |
2009 | 68.51 Thousand USD | 37.5% |
2008 | 49.82 Thousand USD | 38.57% |
2007 | 35.95 Thousand USD | 147.99% |
2006 | 14.5 Thousand USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 1.43 Million USD | 0.0% |
2024 Q2 | 1.29 Million USD | 0.0% |
2023 Q1 | 1.95 Million USD | -6.19% |
2023 FY | 1.57 Million USD | -24.53% |
2023 Q2 | 1.82 Million USD | -6.7% |
2023 Q3 | 1.68 Million USD | -7.35% |
2023 Q4 | 1.57 Million USD | -6.93% |
2022 Q3 | 2.21 Million USD | -5.39% |
2022 FY | 2.08 Million USD | 69333.33% |
2022 Q2 | 2.33 Million USD | 116750.0% |
2022 Q4 | 2.08 Million USD | -5.79% |
2022 Q1 | 2000.00 USD | -33.33% |
2021 Q4 | 3000.00 USD | -25.0% |
2021 Q3 | 4000.00 USD | -95.12% |
2021 Q2 | 82 Thousand USD | -58.38% |
2021 Q1 | 197 Thousand USD | -36.66% |
2021 FY | 3000.00 USD | -99.04% |
2020 FY | 311 Thousand USD | -54.42% |
2020 Q1 | 634 Thousand USD | -7.08% |
2020 Q3 | 420 Thousand USD | -20.45% |
2020 Q4 | 311 Thousand USD | -25.95% |
2020 Q2 | 528 Thousand USD | -16.72% |
2019 Q2 | 940.32 Thousand USD | -9.36% |
2019 Q3 | 841.07 Thousand USD | -10.56% |
2019 Q4 | 682.31 Thousand USD | -18.88% |
2019 FY | 682.31 Thousand USD | 5009.41% |
2019 Q1 | 1.03 Million USD | 7668.72% |
2018 FY | 13.35 Thousand USD | 0.0% |
2018 Q4 | 13.35 Thousand USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q3 | 72.85 Thousand USD | 2.24% |
2012 Q2 | 71.26 Thousand USD | 11.04% |
2012 Q1 | 64.17 Thousand USD | 0.0% |
2012 Q4 | - USD | -100.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | -100.0% |
2011 Q3 | 53.75 Thousand USD | 0.0% |
2011 Q2 | 53.75 Thousand USD | -14.44% |
2011 Q1 | 62.82 Thousand USD | 0.0% |
2010 Q1 | 73.01 Thousand USD | 6.57% |
2010 FY | - USD | -100.0% |
2010 Q2 | 75.36 Thousand USD | 3.22% |
2010 Q3 | 53.63 Thousand USD | -28.84% |
2010 Q4 | - USD | -100.0% |
2009 Q1 | 60.05 Thousand USD | 20.52% |
2009 Q4 | 68.51 Thousand USD | 4.78% |
2009 Q3 | 65.38 Thousand USD | 8.65% |
2009 Q2 | 60.18 Thousand USD | 0.22% |
2009 FY | 68.51 Thousand USD | 37.5% |
2008 Q4 | 49.82 Thousand USD | 6.41% |
2008 Q2 | 41.99 Thousand USD | 7.69% |
2008 Q3 | 46.82 Thousand USD | 11.5% |
2008 FY | 49.82 Thousand USD | 38.57% |
2008 Q1 | 38.99 Thousand USD | 8.45% |
2007 Q3 | 31.45 Thousand USD | 50.95% |
2007 FY | 35.95 Thousand USD | 147.99% |
2007 Q2 | 20.84 Thousand USD | 43.72% |
2007 Q1 | 14.5 Thousand USD | 0.0% |
2007 Q4 | 35.95 Thousand USD | 14.3% |
2006 Q4 | 14.5 Thousand USD | 0.0% |
2006 FY | 14.5 Thousand USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | -217.576% |
Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
Armata Pharmaceuticals, Inc. | 82.3 Million USD | 98.09% |
Azitra, Inc. | 563.69 Thousand USD | -178.876% |
Can-Fite BioPharma Ltd. | 13 Thousand USD | -11992.308% |
Chromocell Therapeutics Corporation | - USD | -Infinity% |
Calidi Biotherapeutics, Inc. | 2.06 Million USD | 23.689% |
CEL-SCI Corporation | 11.6 Million USD | 86.451% |
iBio, Inc. | 3.5 Million USD | 55.175% |
Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 24.058% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 45.699% |
Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 16.013% |
NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -41.877% |
NanoViricides, Inc. | - USD | -Infinity% |
Oragenics, Inc. | - USD | -Infinity% |
BiomX Inc. | 5.4 Million USD | 70.9% |
BiomX Inc. | 5.4 Million USD | 70.9% |
Protalix BioTherapeutics, Inc. | 4.62 Million USD | 65.981% |
Palatin Technologies, Inc. | 163.78 Thousand USD | -859.812% |
Scorpius Holdings, Inc. | 12.61 Million USD | 87.537% |